HELLP Syndrome
Conditions
Keywords
HELLP syndrome, dexamethasone, postpartum period, class I HELLP syndrome
Brief summary
Corticotherapy accelerates maternal postpartum recovery in women with class I HELLP syndrome. The benefit of faster and better recovery would be observed in fewer complications, less utilization of blood products and shorter hospital stay.
Detailed description
Patients with Class I HELLP Syndrome will be recruited for use os dexamethasone or placebo in the puerperium. Effects such as clinical course (blood pressure and diureses), laboratorial behaviour and complications will be compared. Duration of hospitalization will also be accessed.
Interventions
DRUGdexamethasone
Dexamethasone, 10mg (2mL), intravenous, every 12 hours, for 48 hours
DRUGPlacebo
Saline solution, 2 mL, intravenous, every 12 hours, for 48 hours
Sponsors
Instituto Materno Infantil Prof. Fernando Figueira
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
13 Years to 49 Years
Healthy volunteers
No
Inclusion criteria
* Postpartum women with Class I HELLP syndrome
Exclusion criteria
* Chronic users of corticosteroids * Patients with chronic conditions affecting the laboratory parameters involved in the HELLP syndrome * Women who had received antenatal corticosteroids to treat HELLP syndrome were excluded
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| severe maternal morbidity | postpartum | 42 days after delivery |
Secondary
| Measure | Time frame |
|---|---|
| hospital stay duration | postpartum |
Countries
Brazil
Outcome results
None listed